Brokers Issue Forecasts for EBS Q1 Earnings

Emergent BioSolutions Inc. (NYSE:EBS) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Emergent BioSolutions in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earnings per share of $0.27 for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. During the same quarter in the previous year, the company earned ($0.77) earnings per share.

EBS has been the subject of several other reports. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday. Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 9.3 %

Shares of NYSE EBS opened at $5.80 on Thursday. Emergent BioSolutions has a 52-week low of $1.82 and a 52-week high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company’s 50-day simple moving average is $9.43 and its 200-day simple moving average is $9.02. The firm has a market cap of $314.00 million, a price-to-earnings ratio of -1.41 and a beta of 1.62.

Institutional Trading of Emergent BioSolutions

A number of hedge funds and other institutional investors have recently bought and sold shares of EBS. Entropy Technologies LP acquired a new stake in Emergent BioSolutions during the 3rd quarter worth $155,000. Landscape Capital Management L.L.C. acquired a new position in Emergent BioSolutions during the third quarter worth about $141,000. FMR LLC increased its stake in Emergent BioSolutions by 12.6% in the 3rd quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,446 shares in the last quarter. FORA Capital LLC acquired a new position in shares of Emergent BioSolutions during the 3rd quarter worth $103,000. Finally, Hilltop Holdings Inc. lifted its holdings in shares of Emergent BioSolutions by 7.9% in the third quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 12,515 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.